Saturday 17 October 2026
Export PMVP’s income statement to Excel — free account
PMV Pharmaceuticals, Inc.
PMVP Healthcare Biotechnology
In the quarter to June 2026, EPS grew 17.1% and free cash flow grew 20.3%, each against the same quarter a year earlier.
1.21
0.08
−6.20%
Follow PMVP
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (70.93%) | (63.16%) | (55.37%) | (51.87%) |
+8 more TTM periods Free account |
|
| (64.04%) | (58.65%) | (50.51%) | (46.29%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(105.95%) | (89.65%) | (74.72%) | (68.69%) | |
Free Cash Flow per Share |
(1.33) | (1.41) | (1.40) | (1.37) | |
Free Cash Flow |
(71.26) | (74.99) | (73.57) | (72.87) | |
Capital Expenditures |
— | — | 0.00 | 0.18 | |
| Other line items | |||||
Cash ROIC |
(47.22%) | (41.31%) | (33.80%) | (29.12%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | (0.03) | (0.03) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.95 | 0.96 | 0.95 | 0.88 | |
Depreciation/Fixed assets |
(12.03) | (10.77) | (11.13) | (12.75) | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (0.06) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.33) | (1.41) | (1.40) | (1.38) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates